Cardiovascular disease - DiabetesontheNet

The SIGN 154 diabetes guideline and primary care: it’s not just about the glucose

Heart failure and death in new users of SGLT2 inhibitors with and without CVDq

ACE inhibitors and statins in adolescents with type 1 diabetes

Updated guidelines, diabetes prevention, QOF data and flash glucose monitoring

Studies that changed clinical practice. The MICRO-HOPE Study: Evidence for an important role for ACE inhibitors

Association between severe hypoglycaemia and CV outcomes and mortality

Updates from EASD 2017

Don’t Just Screen – Intervene: Protecting the cardiometabolic health of people with severe mental illness

CANVAS and EMPA-REG findings support cardiovascular safety of SGLT2 inhibitors

Breaking news in cardiovascular outcome trials; empagliflozin and stroke; and glycaemic variability in type 1 diabetes

CVD, diabetes complications and care processes in England and Wales

CANVAS trial – cardiovascular benefits, amputations and fractures

Insulin provision therapy associated with higher mortality than insulin sensitising therapy in older people

Vit D or not vit D, that is the question

Studies that changed clinical practice. ACCORD: Action to Control Cardiovascular Risk in Diabetes

PCDS report from the American Diabetes Association’s 77th Scientific Sessions

Cardiovascular disease: The dietary fat debate continues but early tight control is beneficial

Updates from the ADA conference, the NHS RightCare diabetes pathway and more